angiotensin
receptor
blocker
arb
exhibit
major
pleiotrop
protect
effect
beyond
antihypertens
properti
includ
reduct
inflamm
arb
directli
protect
lung
sever
acut
respiratori
syndrom
result
viral
infect
includ
coronaviru
protect
effect
enhanc
arb
administr
reason
arb
therapi
must
continu
patient
affect
hypertens
diabet
renal
diseas
comorbid
current
pandem
control
clinic
studi
conduct
determin
whether
arb
may
includ
addit
therapi
patient
sinc
recent
public
extend
social
media
question
therapeut
use
angiotensin
receptor
blocker
arb
treatment
cardiovascular
kidney
metabol
disord
may
becom
comorbid
import
summar
reason
ongo
arb
treatment
diseas
may
discontinu
must
maintain
develop
diseas
angiotensin
receptor
stimul
major
mechan
drive
circulatori
also
local
reninangiotensin
system
ra
involv
regul
multipl
function
organ
includ
lung
increas
ra
activ
enhanc
stimul
major
injuri
factor
affect
brain
cardiovascular
renal
function
lipid
glucos
metabol
immun
system
point
inflammatori
lung
diseas
arb
effect
block
initi
develop
treat
hypertens
exhibit
uniqu
pleiotrop
protect
effect
beyond
antihypertens
properti
arb
directli
reduc
inflamm
organ
fibrosi
endotheli
injuri
protect
mitochondri
function
maintain
insulin
sensit
energi
metabol
protect
lipid
metabol
normal
coagul
cascad
properti
consid
benefit
patient
acut
critic
disord
tabl
reason
arb
success
use
first
line
antihypertens
also
treatment
diabet
kidney
diseas
congest
heart
failur
cerebrovascular
diseas
major
benefici
effect
arb
capac
reduc
inflamm
endotheli
epitheli
dysfunct
mani
organ
arb
directli
protect
lung
endotheli
barrier
integr
lung
disrupt
acut
injuri
includ
produc
mani
virus
substanti
clinic
evid
direct
effect
arb
treatment
thu
protect
lung
sever
injuri
associ
pneumonia
sepsi
influenza
mortal
reduc
patient
treat
arb
cardiovascular
disord
later
hospit
pneumonia
cerebr
malaria
also
present
endotheli
dysfunct
enhanc
proinflammatori
cytokin
product
enhanc
coagul
complement
activ
rodent
model
addit
arb
therapeut
arsen
report
reduc
mortal
addit
appear
treatment
arb
dramat
reduc
mortal
ebola
outbreak
africa
although
report
fulli
valid
fang
colleagu
diaz
hypothes
patient
treat
arb
may
higher
risk
develop
sever
fatal
complic
infect
sever
acut
respiratori
syndrom
coronaviru
respons
recommend
prevent
measur
withdraw
arb
therapeut
arsen
treat
ongo
cardiovascular
kidney
metabol
disord
possibl
comorbid
author
base
recommend
demonstr
arb
administr
increas
express
receptor
sar
cov
author
hypothes
increas
express
receptor
would
enhanc
viral
uptak
although
without
scientif
evid
author
predict
arb
may
also
enhanc
viral
uptak
facilit
infect
diaz
support
recommend
basi
analysi
chines
patient
infect
report
sever
outcom
includ
death
patient
suffer
cardiovascular
kidney
disord
diabet
like
treat
arb
howev
analysi
report
reveal
studi
address
use
arb
patient
data
previou
arb
use
patient
later
infect
compar
frequenc
arb
use
gener
popul
suffer
cardiovascular
disord
current
avail
furthermor
argument
children
may
protect
develop
crossprotect
antibodi
infect
common
cold
alpha
coronaviru
scientif
basi
sinc
associ
never
demonstr
statement
children
may
protect
infect
reduc
respect
elderli
erron
protein
enzymat
activ
declin
postnat
importantli
elderli
lower
express
enhanc
angiotensin
ii
proinflammatori
effect
inform
support
hypothesi
protect
effect
arb
older
individu
risk
feng
colleagu
correct
point
arb
treatment
increas
possibl
comorbid
hypertens
diabet
howev
specul
treatment
enhanc
infect
viru
without
scientif
evid
suggest
replac
arb
therapi
altern
antihypertens
medic
take
consider
altern
like
use
calcium
channel
blocker
lack
major
pleiotrop
benefici
characterist
arb
argument
arbdepend
upregul
may
directli
enhanc
infect
ignor
complex
function
metabol
regul
appar
inconsist
paradox
find
includ
find
multipl
substrat
beyond
angiotensin
ii
receptor
also
inhibit
angiotensin
cascad
contribut
control
excess
activ
substanti
preclin
clinic
data
support
propos
upregul
benefici
sever
disord
mani
report
demonstr
may
amelior
acut
lung
injuri
result
reduc
activ
beyond
effect
blood
pressur
emerg
potent
physiolog
neg
regul
ra
imbalanc
activ
system
andor
local
propos
import
contributor
mani
diseas
pathogenes
includ
inflammatori
lung
diseas
addit
indirectli
upregul
arb
enhanc
axi
mayor
protect
system
reduc
elderli
balanc
ang
ii
overstimul
reduc
inflamm
associ
downregul
sever
kinas
signal
pathway
tabl
agreement
posit
statement
esc
council
hypertens
ace
inhibitor
angiotensin
receptor
blocker
previou
report
think
scientif
evid
support
replac
arb
subject
suffer
yet
infect
remov
arb
therapeut
arsen
enhanc
ang
receptor
activ
potenti
worsen
lung
inflamm
associ
comorbid
infect
although
arb
well
toler
elderli
administr
drug
includ
arb
patient
must
continu
care
monitor
imper
data
analysi
perform
determin
whether
continu
ongo
arb
treatment
comorbid
disord
improv
outcom
reduc
mortal
patient
b
improv
outcom
reduc
mortal
diseas
confirm
whether
addit
arb
therapeut
arsen
patient
suffer
comorbid
disord
previous
medic
compound
improv
outcom
diseas
c
condit
met
expand
treatment
arb
patient
suffer
cardiovascular
metabol
disord
suscept
arb
therapi
medic
compound
expos
may
protect
patient
tragic
consequ
author
conflict
interest
declar
respect
manuscript
tabl
propos
protect
mechan
arb
administr
patient
reduct
lung
edema
vascular
permeabl
epitheli
endotheli
cell
injuri
decreas
apoptosi
pulmonari
edema
pulmonari
fibrosi
reduct
profibrot
transform
growth
factor
beta
inhibit
coagul
cascad
enhanc
activ
mesodermderiv
mesenchym
stem
cell
msc
involv
repair
injur
lung
reduct
proinflammatori
cytokin
chemokinin
reactiv
oxygen
speci
ro
inflammatori
macrophag
infiltr
downregul
proinflammatori
kinas
cascad
pathway
macrophag
polar
decreas
macrophag
infiltr
reduct
late
mediat
inflamm
high
mobil
group
box
mainten
insulin
sensit
energi
metabol
protect
mitochondri
function
overal
effect
blockad
antihypertens
effect
enhanc
activ
tabl
includ
limit
major
protect
mechan
sever
acut
respiratori
syndrom
confirm
arb
administr
pharmacolog
research
